New analysis tracks life-years gained from blood cancer therapies, revealing breakthrough inflection points, stubborn AML gaps, and inequities in access.
|Videos|October 30, 2017
Progress With Monoclonal Antibodies in Plasma Cell Neoplasms
Author(s)Sandy Wong, MD
Sandy Wong, MD, assistant professor, Division of Hematology/Oncology, UCSF School of Medicine, discusses the progress that has been made with monocloncal antibodies for the treatment of plasma cell neoplasms.
Advertisement
Advertisement
Related to this article
Five myeloma experts share their top takeaways from IMS 2026, including the CERVINO trial and long-term follow-up from the PERSEUS study.
Benjamin Herzberg, MD, discusses KRAS-mutant non–small cell lung cancer, upfront biomarker testing, and the emerging RAS inhibitor toolkit on Targeted Talks.
Broad oncology bundles falter; experts push smaller surgery/radiation episodes, better navigation, and AI analytics to improve value-based care.
In an interview, Peter Voorhees, MD, discusses his presentation of the CERVINO trial data from the International Myeloma Society meeting.
For Prostate Cancer Awareness Month, Herbert Lepor, MD, discusses the leading concerns in managing early prostate cancer and tailoring strategies to the patient based on their risk and goals.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Giredestrant Plus Everolimus Improves PFS in ER+ Advanced Breast Cancer
2
New Drug Application Filed for Savolitinib/Osimertinib in MET+ NSCLC
3
Oral Azacitidine-Cedazuridine Meets Pharmacokinetic Goal in Phase 3 MDS/CMML Trial
4
Denosumab Biosimilar Approved For Existing Oncology Indications
5